Prosecution Insights
Last updated: November 04, 2026
Application No. 19/246,240

Wearable for Breast Cancer Detection

Final Rejection §DP
Filed
Jun 23, 2025
Priority
Jul 17, 2024 — provisional 63/672,676 +2 more
Examiner
MINCHELLA, ADAM ZACHARY
Art Unit
3794
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Jano Life Inc.
OA Round
4 (Final)
64%
Grant Probability
Moderate
5-6
OA Rounds
2y 0m
Est. Remaining
98%
With Interview

Examiner Intelligence

Grants 64% of resolved cases
64%
Career Allowance Rate
239 granted / 373 resolved
-5.9% vs TC avg
Strong +34% interview lift
Without
With
+33.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
41 currently pending
Career history
415
Total Applications
across all art units

Statute-Specific Performance

§101
3.3%
-36.7% vs TC avg
§103
49.2%
+9.2% vs TC avg
§102
16.5%
-23.5% vs TC avg
§112
24.6%
-15.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 373 resolved cases

Office Action

§DP
DETAILED ACTION This action is pursuant to the claims filed on 06/15/2026. Claims 1-6, 9, 11-26 are pending. A final action on the merits of claims 1-6, 9, 11-26 is as follows. Response to Amendment Applicant’s amendment to the claims are acknowledged and entered accordingly. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-6, 9, 11-20 and 25-26 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 41-60 of copending Application No. 19/196,572 in view of Nachaliel. This is a provisional nonstatutory double patenting rejection. Regarding claim 1, the reference claims recite each of the limitations of instant claim except for one electrode of the plurality of electrodes being a ring electrode having a hole sized to accept a nipple. In related prior art, Nachaliel teaches a similar cancer detection system comprising a ring electrode having a hole sized to accept a nipple ([0108]) and further teaches measurement of the nipple provides lower impedance relative to other surfaces of the breast and providing a ring electrode to receive the nipple reduces the pressing of the nipple into the breast ([0108]). Therefore it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to have modified the device of Mamigonians in view of Melamed and Nachaliel to incorporate one ring electrode having a hole sized to receive a nipple to arrive at claim 1. Doing so would advantageously enable the device to gather signals from a location of the breast having lower impedance than other surfaces of the breast ([0106]) while also avoiding pressing the nipple into the breast to minimize patient discomfort ([0108]). Regarding claims 2-6, each of reference claims 42-46 respectively correspond to instant claims 2-6. Therefore it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention the reference claims in view of Nachaliel to arrive at each of claims 2-6. Doing so would simply be combining known elements to yield predictable results therein. Regarding claims 9, and 11-20, reference claims 49 and 51-60 respectively correspond to instant claims 9 and 11-20. Therefore it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention the reference claims in view of Nachaliel to arrive at each of claims 9 and 11-20. Doing so would simply be combining known elements to yield predictable results therein. Regarding claim 25, reference claim 60 corresponds to instant claim 25. Therefore it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention the reference claims in view of Nachaliel to arrive claim 25. Doing so would simply be combining known elements to yield predictable results therein. Regarding claim 26, reference claim 47 recites the positioning logic based on electro-cardio signals and reference claim 1 recites the application of probe electrical signals applied to the user. Therefore it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention have modified the reference claims in view of Nachaliel to incorporate the step of the positioning logic being configured to determine where the probe electrical signals are applied to arrive at claim 26. Using the positioning logic of the reference claims to determine where the probe electrical signals are applied would be a simple combination of two well-known elements to yield predictable results therein (i.e., using a calculated position of a probe electrode based on electro-cardio signals to correlate said calculated position with a position in which the probe electrical signals were applied). Claims 21-24 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 41-60 of copending Application No. 19/196,572 in view of Nachaliel in view of McKenna. This is a provisional nonstatutory double patenting rejection. Regarding claims 21-24, the reference claims fail to explicitly recite detected position being a detected orientation, wherein the positioning logic is configured to detect a position of the electrode array based on an ECG signal; wherein the positioning logic is configured to detect movement of the electrode array relative to a heart of the user; wherein in the movement includes breathing of the user. In related prior art, McKenna teaches a similar device comprising positioning logic configured to detect an oreientation of the electrode array based on detection of ECG signals (Figs 7-8, and 15,[0037-0038] discloses ECG signals and sensor location classification algorithms based on sensed data to determine positions of sensors; examiner notes under the broadest reasonable interpretation “an orientation” can be interpreted to be “a position”, the detected movement of the electrodes of McKenna is necessarily relative to the heart, and the detected movement can be from breathing by the patient). Therefore it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to have modified Mamigonians in view of McKenna to incorporate the positioning logic configured to detect a position of the electrode array based on detect ECG signals to arrive at claims 21-24. Doing so would advantageously enable the device with the ability to self-determine the position of its electrode array to indicate whether the sensors are correctly or incorrectly applied to a user (see Fig 16, steps 140/144). Allowable Subject Matter The following is a statement of reasons for the indication of allowable subject matter: Regarding claims 1-6, 9, 11-26, the Mamigonians, Melamed, Nachaliel, McKenna, Davies, Ramahi, Cantu, Gimzewski, Stoval references fail to teach the system of claims 1-6, 9, 11-26 comprising an electrode array configured to be worn by a user in contact with skin of the user, the electrode array including a plurality of electrodes, one electrode of the plurality of electrodes being a ring electrode having a hole sized to accept a nipple; a power source; a signal generator configured to apply probe electrical signals to one or more of the plurality electrodes using the power source; a detector configured to detect response electrical signals at one or more of the plurality of electrodes and to generate digital signal outputs, the response electrical signals being responsive to the probe electrical signals and the digital signal outputs being representative of a physiological state of a tissue of the user; control logic configured to activate the signal generator to generate a series of the probe electrical signals over a period of time, each of the probe electrical signals resulting in at least one of the response electrical signals; positioning logic configured to detect a position of the electrode array based on detection of electro-cardio signals using the electrode array; memory configured to store the digital signal outputs; trained machine learning logic configured to detect a physiological state of the user based on the digital signal outputs, the physiological state being indicative of cancer; and an 11O configured to communicate the digital signal output to the trained machine learning logic. Mamigonians discloses a similar system for cancer detection including an electrode array, power source, signal generator, detector, and control logic to generate probe electrical signals, response electrical signals, and digital output signals as claimed. Mamigonians fails to teach the logic being trained machine learning logic, a positioning logic configured to detect a position of the electrode array based on detection of electro-cardio signals using the electrode array, and one electrode of the plurality of electrodes being a ring electrode having a hole sized to accept a nipple. The Melamed reference discloses a similar medical system comprising the use of trained machine learning. The Nachaliel reference discloses the use of a ring electrode having a hole sized to accept a nipple. The McKenna reference discloses a system for determining sensor placement based on received patient sensor waveforms. However, a combination modifying the Mamigonians reference to incorporate a ring electrode sized to accept a nipple as well as modifying the sensors of Mamigonians to measure electro-cardio signals to detect a position of the electrode would result from impermissible hindsight benefit using information solely gleaned from the applicant’s specification. The Mamigonians reference is directed to flexible dome shaped substrate to ensure close contact is made with the electrodes and corresponding breast tissue (see [0040-0041] and Fig 1), such that there would be no reasonable motive or need to incorporate positioning logic to determine a position of the electrode array based on electro-cardio signals. No other pertinent prior art reference were found that would overcome the above deficiencies. Therefore, there is no motivation (either in these references or elsewhere in the art) for making such specific and significant modifications thereto to arrive at claim(s) 1-6, 9, 11-26. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Adam Z Minchella whose telephone number is (571)272-8644. The examiner can normally be reached M-Fri 7-3 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Joseph Stoklosa can be reached at (571) 272-1213. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ADAM Z MINCHELLA/Primary Examiner, Art Unit 3794
Read full office action

Prosecution Timeline

Show 1 earlier event
Aug 21, 2025
Non-Final Rejection mailed — §DP
Nov 21, 2025
Response Filed
Dec 09, 2025
Final Rejection mailed — §DP
Mar 04, 2026
Request for Continued Examination
Mar 24, 2026
Response after Non-Final Action
Apr 08, 2026
Non-Final Rejection mailed — §DP
Jul 06, 2026
Response Filed
Sep 21, 2026
Final Rejection mailed — §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778481
AMBULATORY ELECTROCARDIOGRAM PATCH DEVICES AND METHODS
3y 4m to grant Granted Nov 03, 2026
Patent 12773263
BIPOLAR ABLATION GRAPHICAL USER INTERFACE
4y 11m to grant Granted Oct 27, 2026
Patent 12773149
PHYSIOLOGICAL SIGNAL ACQUISITION DEVICES AND WEARABLE DEVICES
2y 4m to grant Granted Oct 27, 2026
Patent 12751764
Ablation Device and Ablation System
3y 3m to grant Granted Oct 06, 2026
Patent 12751669
ELECTRODE CATHETER
2y 8m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
64%
Grant Probability
98%
With Interview (+33.7%)
3y 5m (~2y 0m remaining)
Median Time to Grant
High
PTA Risk
Based on 373 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month